Brokers Offer Predictions for Celsion Corporation’s Q4 2017 Earnings (CLSN)
Celsion Corporation (NASDAQ:CLSN) – Equities research analysts at Oppenheimer Holdings issued their Q4 2017 earnings estimates for Celsion Corporation in a report issued on Monday. Oppenheimer Holdings analyst H. Singh anticipates that the biotechnology company will post earnings of ($0.29) per share for the quarter. Oppenheimer Holdings has a “Outperform” rating and a $9.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Celsion Corporation’s FY2018 earnings at ($1.21) EPS, FY2019 earnings at ($1.32) EPS and FY2020 earnings at ($0.94) EPS.
Other analysts have also recently issued research reports about the company. Maxim Group reissued a “hold” rating on shares of Celsion Corporation in a research report on Tuesday, August 15th. Zacks Investment Research lowered Celsion Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, ValuEngine lowered Celsion Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $11.90.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/23/brokers-offer-predictions-for-celsion-corporations-q4-2017-earnings-clsn.html.
An institutional investor recently bought a new position in Celsion Corporation stock. Sabby Management LLC acquired a new position in Celsion Corporation (NASDAQ:CLSN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned 1.30% of Celsion Corporation as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.41% of the company’s stock.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.